Bob Karr
2 min read
In This Article:
Ardelyx, Inc. (NASDAQ:ARDX) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers. On June 18, H.C. Wainwright began coverage on the company’s stock with a “Buy” rating and a price objective of $10.00. The firm highlighted Ardelyx, Inc. (NASDAQ:ARDX)’s successful commercialization of bowel and kidney disease treatments.
An aerial view of a pharmaceutical facility, showing the size and scale of the company's operations.
The firm mentioned about Ardelyx, Inc. (NASDAQ:ARDX)’s demonstrated approval and commercial execution with IBSRELA for irritable bowel syndrome with constipation in adults and XPHOZAH for treating hyperphosphatemia in adults having chronic kidney disease on dialysis. Overall, the firm expects near-term commercial progress for Ardelyx, Inc. (NASDAQ:ARDX). The company delivered a strong Q1 2025, garnering $74 million in total revenue. As IBSRELA enters its 3rd full year on the market, it saw strong YoY growth of 57%.
The US net product sales revenue for IBSRELA during Q1 2025 came in at $44.4 million. This growth was supported by increases throughout key demand indicators, which include total writers and new and refill prescriptions. The US net product sales revenue for XPHOZAH during Q1 2025 came in at $23.4 million, thanks to the strong commercial momentum and execution.
Ardelyx, Inc. (NASDAQ:ARDX) is engaged in discovering, developing, and commercializing medicines to treat unmet medical needs.
While we acknowledge the potential of ARDX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ARDX and that has 100x upside potential, check out our report about this cheapest AI stock.
READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now
Disclosure: None.
